Cheers foxy its 1 i have that i dont even look at much and have...

Cheers foxy its 1 i have that i dont even look at much and have put it away for long term as i believe it has the potential do for pancreatic and liver cancers what Sirtex did for both liver and prostate cancer. Oncosil's extension of brachytherapy into the pancreatic area may well be the big step needed in the treatment of pancreatic cancer. The disease has a poor prognosis and with Sirtex leading the way in internal radiation therapies Oncosil may well follow both with treatments that will help in a crippling disease but also in share price growth for holders in a company which is on a path to some major breakthroughs in this space. We are talking about a disease where usually diagnosis means there is not much hope but Oncosil can safely deliver a large dose of radiation in early treatment which de-escalate primary tumours which in turn will lead to a reduction in pain and the risk of metastatic development and death. The survival rate currently in the pancreatic cancer space is very poor with only 15% of newly diagnosed cases being resectable where the whole tumour is removed which leads to possible cure. The rest using 2 current chemotherapy drugs gemcitabine and abraxane have shown to extend life sufficiently to be considered standard of care. So this places Oncosil in the box seat to become a major player in the treatment in the pancreatic space.

The path to approval and development for Oncosil is another reason i believe the growth for this stock will be massive. The FDA's new approval pathway for medical devices for breakthrough treatments will see an opportunity for a quick path to commercialisation when compared to the normal path for investors in the biotech space. The boxes needed to be ticked for Oncosil to meet the criteria of breakthrough treatment fit in perfectly to Oncosils treatment. The FDA's guidance to get accelerated pathway says the treatment needs to treat an irreversible life threatening disease and it needs only meet 1 of the following requirements being it it does represent a breakthrough technology that provides a clinically meaningful advantage over existing legally marketed technology, no approved alternative treatment or means of diagnosis exists or the device offers significant clinically meaningful advantages over existing legally marketed alternatives. Getting accelerated approval pathway means the FDA would approve on lesser endpoints.

Oncosil's board has a good mix in the medical and scientific side with a strong scientific team as well but i would not be surprised to see some strengthening of the board at some stage as developments move forward in particular as the US phase of trials move forward. Oncosil is a stock that i am very confident that will 1 day be looked back on like the Sirtex's where people who thought about it but didn't will think gee i missed a big opportunity on the next big AUS medical company. Who remembers Sirtex under $1 and thought about it. It was in 2002 and i remember looking at it after the tech wreck but i had been hammered in the wreck but i wish it was 1 i picked up. Oncosil i believe will 1 day be looked back on similarly in the future. Some may already be wondering why they didn't jump on back when this was under 10c but even now the gains are massive in the future from these levels with the potential unfolding here.